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The process for the development of the Canadian Diabetes Asso-
ciation 2013 Clinical Practice Guidelines for the Prevention and Man-
agement of Diabetes in Canada included provisions to update
individual chapters prior to the planned published revision in 2018
in the event of signiﬁcant changes in evidence supporting the rec-
ommendations (1). In the case of new recommendations or changes
to existing recommendations, the process of updating would be the
same as the 2013 revision, including the Independent Method-
ological Review (1).
Since the publication of the 2013 guidelines, several cardiovas-
cular outcome trials have been completed, and they demonstrate
the overall cardiovascular safety of 3 dipeptidyl peptidase-4 (DPP-4)
inhibitors (alogliptin, saxagliptin, sitagliptin) and 1 glucagon-like-
protein-1 (GLP-1) receptor agonist (lixisenatide) in patients with
type 2 diabetes who are at high risk for cardiovascular events (2–5).
Noninferiority of the primary cardiovascular composite endpoints
was achieved, and saxagliptin demonstrated an unexpected increase
in hospitalization for heart failure that has yet to be fully explained
(2–5). More recently, the ﬁrst cardiovascular outcome trial of the
sodium glucose linked transporter 2 (SGLT2) inhibitor class was pub-
lished, and it demonstrated cardiovascular superiority, thereby quali-
fying as a practice-changing study (6).
The Empagliﬂozin Cardiovascular Outcome Event Trial (EMPA-
REG OUTCOME) included 7020 patients with type 2 diabetes and
clinical cardiovascular disease (CVD), including prior myocardial
infarction (MI), coronary artery disease, unstable angina, stroke or
occlusive peripheral arterial disease and estimated glomerular ﬁl-
tration rate (eGFR) levels ≥30 mL/min. They were randomized to 2
different dosages of empagliﬂozin (10 mg or 25 mg) or placebo on
top of standard care. More than 98% of the patients were receiv-
ing antihyperglycemic agents prior to randomization, and approxi-
mately 75% were taking metformin. Baseline glycated hemoglobin
(A1C) levels were in the 7% to 10% range, with a mean A1C level
of 8.1%, and 82% had had diabetes for more than 5 years (6). Approxi-
mately 80%were taking renin-angiotensin-aldosterone system inhibi-
tors, statins and acetylsalicylic acid (6).
The primary outcome was a composite cardiovascular end-
point of death from cardiovascular causes, nonfatal MI or nonfatal
stroke and occurred less commonly in the group taking empagliﬂozin
(both doses combined) compared to recipients of placebo (10.5%
vs. 12.1%; hazard ratio [HR], 0.86; p<0.001 for noninferiority, p=0.04
for superiority). The reduction in the primary endpoint was driven
mainly by a 38% relative risk reduction (p<0.001) in cardiovascu-
lar death because there was no reduction in the rate of nonfatal MI
or nonfatal stroke. Empagliﬂozin therapy was also associated with
a 35% relative risk reduction (p=0.002) of hospitalization for heart
failure and a 32% relative risk reduction (p<0.001) of total mortal-
ity. There weremodest metabolic beneﬁts and, overall, empagliﬂozin
was well tolerated, although genital infections occurred at a higher
rate in patients treated with empagliﬂozin (6).
The results of EMPA-REG OUTCOME are relevant to the manage-
ment of type 2 diabetes because 40% to 60% of these individuals will
die of cardiovascular disease, and the published literature to date
shows little evidence that other antihyperglycemic agents provide
cardiovascular beneﬁts in patients with clinical CVD (7,8). Less than
2% of patientswere drug naive, and patients typically had longstanding
diabetes and were taking background antihyperglycemic therapies.
The outcomes in the small number of drug-naive patients were not
reported. Therefore, empagliﬂozin should be utilized in patients
with type 2 diabetes and clinical CVD who are already taking
antihyperglycemic therapy. EMPA-REG OUTCOME is the ﬁrst com-
pleted cardiovascular outcome trial to include an SGLT2 inhibitor, so
it is currently unknown whether the other members of this class
provide the same CV beneﬁts. CV outcome trials with the other SGLT2
inhibitors are ongoing (9,10). The management of hyperglycemia in
type 2 diabetes is summarized in Figure 1, which integrates the
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Figure 1. Management of hyperglycemia in type 2 diabetes.
CHF, congestive heart failure; CVD, cardiovascular disease; DPP, dipeptidyl peptidase; eGFR, estimated glomerular ﬁltration rate; GI, gastrointestinal; GLP-1R, glucagon-like-
protein-1 receptor; LDL-C, low density lipoprotein cholesterol; SGLT2, sodium glucose link transporter 2; UTI, urinary tract infection.
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ﬁndings of EMPA-REGOUTCOME by prioritizing the presence of clini-
cal cardiovascular disease when adding an antihyperglycemic and
choosing an SGLT2 inhibitor with demonstrated CV beneﬁts in this
patient population. As part of individualized pharmacotherapyman-
agement for all patients with type 2 diabetes, the presence of CVD
or multiple risk factors and the effect of antihyperglycemic agents
on CV outcomes should also be considered; hence, the addition of
the column titled “Effect in Cardiovascular Outcome Trial” to the phar-
macotherapy table. Only data fromprospective randomized controlled
trials of CV outcomes with a speciﬁc antihyperglycemic agent were
included in this column. Therefore, in addition to the data from recent
trials of incretin and an SGLT2 inhibitor, the new column includes
the CV neutrality of insulin glargine (11) and thiazolidinediones
(12,13) in CV outcome trials. As future cardiovascular outcome trials
of antihyperglycemic agents are published, the guidelines commit-
tee will continue to assess new evidence and update as appropriate.
Recommendations (Changes from 2013 are in bold-face type)
1. In people with a new diagnosis of type 2 diabetes:
i. Metformin may be used at the time of diagnosis, in con-
junction with lifestyle management (Grade D, Consensus).
ii. If A1C <8.5% and glycemic targets are not achieved using
lifestyle management within 2 to 3 months, antihyper-
glycemic agent therapy with metformin should be initi-
ated (Grade A, Level 1A) (14).
iii. If A1C levels are ≥8.5%, antihyperglycemic agents should be
initiated concomitantly with lifestylemanagement, and con-
sideration should be given to initiating combination therapy
with 2 agents, 1 of which may be insulin (Grade D,
Consensus)
iv. Individuals with symptomatic hyperglycemia and meta-
bolic decompensation should receive an initial antihyper-
glycemic regimen containing insulin with or without
metformin (Grade D, Consensus).
2. Metformin should be the initial drug used in monotherapy
(Grade A, Level 1A) (15,16) for overweight patients; Grade D,
Consensus for nonoverweight patients).
3. Other classes of antihyperglycemic agents, including insulin,
should be added to metformin, or used in combination
with each other, if glycemic targets are not met, taking into
account the information in Figure 1 and the table available at
http://guidelines.diabetes.ca/cdacpg_resources/Ch13_Table1
_Antihyperglycemic_agents_type_2_2016.pdf (Grade D, Con-
sensus), and these adjustments to and/or additions of
antihyperglycemic agents should be made in order to attain
target A1C levels within 3 to 6 months (Grade D, Consensus).
4. In people with clinical cardiovascular disease in whom gly-
cemic targets are not met, an SGLT2 inhibitor with demon-
strated cardiovascular outcome beneﬁt should be added to
antihyperglycemic therapy to reduce the risk for cardiovas-
cular and all-cause mortality (Grade A, Level 1A for
empagliﬂozin) (6).
5. Choice of additional pharmacologic treatment agents should
be individualized by patient’s characteristics, taking into con-
sideration (Grade D, Consensus):
■ Degree of hyperglycemia
■ Risk of hypoglycemia
■ Overweight or obesity
■ Cardiovascular disease or multiple risk factors
■ Comorbidities (renal, congestive heart failure, hepatic, etc.)
■ Preferences of the patient
■ Access to treatment
6. When basal insulin is added to antihyperglycemic agents, long-
acting analogues (detemir or glargine) may be used instead of
intermediate-acting Neutral Protamine Hagedorn (NPH) to
reduce the risk for nocturnal and symptomatic hypoglycemia
(Grade A, Level 1A) (17–19).
7. When bolus insulin is added to antihyperglycemic agents, rapid-
acting analogues may be used instead of regular insulin to
improve glycemic control (Grade B, Level 2) (20) and to reduce
the risk for hypoglycemia (Grade D, Consensus).
8. All individuals with type 2 diabetes currently using or start-
ing therapy with insulin or insulin secretagogues should be
counselled about the prevention, recognition and treatment of
drug-induced hypoglycemia (Grade D, Consensus).
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